IP Library Granted Patent US 8,992,888
Granted Patent B2
US 8,992,888 · App. 13/658,929 · Granted Mar 31, 2015

Radiographic contrast agent for postmortem, experimental and diagnostic angiography

Inventors: Silke Grabherr (Murten, CH); Erich Gygax (Bern, CH)
Assignee: Forim-X AG
A61K49/0457A61K49/0409A61K49/0438
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,992,888
App. No.
13/658,929
Granted
Mar 31, 2015
Kind
B2
Abstract

A contrast agent for angiography is disclosed, in particular, for examining animal or human bodies or components thereof such as members or organs thereof, comprising an essentially oil-based apolar contrast component for X-ray examinations, the contrast component having a contrast component viscosity in the range of 30-100 mPas. The contrast agent is characterized in that the contrast component is present in a mixture with at least one further apolar component, the viscosity of which is less than or at most equal to the contrast component viscosity. Methods for angiography examination are also disclosed, in which such a contrast agent or also a polar contrast agent are used at least periodically and applications of such contrast agents.

Claims (16)

1. A contrast agent for postmortem, experimental or diagnostic angiography and for examination of animal or human corpses or components thereof, comprising:

an essentially oil-based, non-polar contrast component for X-ray examinations, said contrast component having a contrast component viscosity in the range of 30-100 mPas,

wherein the contrast component is present in a mixture with only one further non-polar component, which is a 12-16 carbon atom alkane of a viscosity that is lower or at the most equal to the contrast component viscosity.

2. The contrast agent according to claim 1 , wherein the contrast component has a viscosity in the range of 30-80 mPas.

3. The contrast agent according to claim 2 , wherein the contrast component is an iodine-based or sulphur-based radiographic contrast agent.

4. The contrast agent according to claim 1 , wherein the further non-polar component has a viscosity in the range of 0.2-80 mPas.

5. The contrast agent according to claim 1 , wherein the further non-polar component has a viscosity in the range of 2-4 mPas.

6. The contrast agent according to claim 1 , wherein the volume-ratio of the contrast component to the further non-polar component is in the range of 1:1-1:10.

7. A method for the angiographic examination of animal or human corpses or components thereof, wherein a contrast agent according to claim 1 is introduced into the vascular system and wherein, subsequently or synchronously, radiographic images are recorded by the aid of X-rays.

8. The method according to claim 7 , wherein prior to the introduction of the contrast agent, the circulatory system is rinsed by using a non-polar component or a NaCl- or lactate-solution.

9. The contrast agent according to claim 1 , wherein the 12-16 carbon atom alkane is an n-alkane.

10. The contrast agent according to claim 1 , wherein the contrast component is an iodized or brominated component or oil.

11. The contrast agent according to claim 1 , wherein the further non-polar component has a viscosity in the range of 2-60 mPas.

12. The contrast agent according to claim 6 , wherein the volume-ratio of the contrast component to the further non-polar component is in the range of 1:4-1:6.

13. The contrast agent according to claim 10 , wherein the contrast component is selected from the group consisting of a propyliodone, a fatty-acid-ethyl ester of iodized poppy-seed oil, and an iodipine.

14. The contrast agent according to claim 1 , wherein the further non-polar component is hexadecane or tetradecane.

Assignments (1)
MERGER Recorded Oct 20, 2017
From: FORIM-X AG
To: FUMEDICA AG
Reel/Frame 043916/0599 →
Priority Claims (2)
CH 1485/06 · Sep 18, 2006 · national
CH 212/07 · Feb 8, 2007 · national
Continuity (2)
Continuation 12441822
Related Publication 20130045168A1 · Feb 21, 2013